MCAS

MCAS
Name	Mast Cell Activation Syndrome
Synonyms	MCAS
Field	Immunology, Allergy and immunology, Hematology
Symptoms	Flushing, pruritus, hypotension, gastrointestinal distress, neuropsychiatric symptoms
Complications	Anaphylaxis, osteoporosis, organ damage
Onset	Any age
Duration	Chronic
Types	Primary, secondary, idiopathic
Causes	Clonal mast cell disorder, immune dysregulation, hereditary alpha tryptasemia
Risks	Atopy, autoimmune disease
Diagnosis	Based on clinical criteria, elevated serum tryptase, N-methylhistamine
Differential	Mastocytosis, carcinoid syndrome, pheochromocytoma
Treatment	Mast cell stabilizers, H1 antagonists, H2 antagonists, leukotriene antagonists
Medication	Cromolyn sodium, ketotifen, omalizumab
Prognosis	Variable; chronic management often required
Frequency	Under investigation; potentially underdiagnosed

MCAS. Mast Cell Activation Syndrome is a chronic multi-system disorder characterized by inappropriate and recurrent activation of mast cells, leading to a wide range of inflammatory and allergic-type symptoms. The condition is diagnosed based on a combination of clinical findings and laboratory evidence of mast cell mediator release, distinguishing it from related disorders like systemic mastocytosis. Management focuses on symptom control through a combination of pharmacologic agents and trigger avoidance, requiring often lifelong treatment strategies.

Definition and overview

MCAS is defined by a consensus framework requiring the presence of typical clinical symptoms affecting at least two organ systems, a measurable increase in validated mast cell mediators during symptomatic episodes, and a positive response to medications that target mast cell mediators or activity. It exists as a spectrum within the broader category of mast cell activation diseases, sitting diagnostically between allergic reactions and the neoplastic proliferation seen in mastocytosis. The syndrome can be classified as primary, where there is an underlying clonal mast cell abnormality; secondary, triggered by a specific identifiable condition like an IgE-mediated allergy or autoimmune disorder; or idiopathic, where no clear driver is found. Its recognition has grown significantly within fields like clinical immunology and allergology since the early 21st century, influenced by work from researchers at institutions like the National Institutes of Health and the University of Bonn.

Causes and pathophysiology

The fundamental pathophysiology involves the aberrant release of preformed and newly synthesized inflammatory mediators from mast cells, such as histamine, heparin, tryptase, prostaglandin D2, and leukotrienes. In primary MCAS, this dysregulation is often linked to acquired gain-of-function mutations in the KIT gene, similar to those found in systemic mastocytosis but without meeting the full World Health Organization diagnostic criteria for that disease. Secondary MCAS may be driven by chronic inflammatory states seen in conditions like Ehlers-Danlos syndrome, postural orthostatic tachycardia syndrome (POTS), or persistent chronic infections. A hereditary form is associated with hereditary alpha tryptasemia, a genetic trait involving increased TPSAB1 gene copy number. Triggers for acute episodes are highly variable and can include non-steroidal anti-inflammatory drugs, opioids, physical stimuli like heat or pressure, emotional stress, and certain foods.

Signs and symptoms

Symptoms are episodic, fluctuating, and can involve nearly every organ system, creating a complex clinical picture often mistaken for other illnesses. Cutaneous manifestations are extremely common and include flushing, urticaria, angiosedema, and a sense of crawling pruritus. Cardiovascular system involvement may present as tachycardia, hypotension mimicking vasovagal syncope, or even anaphylactic shock. Gastrointestinal tract symptoms range from nausea and abdominal cramping to diarrhea and malabsorption. Neurological and neuropsychiatric symptoms, such as brain fog, migraine, paresthesia, and anxiety, are frequently reported. Other possible effects include musculoskeletal pain, nasal congestion, conjunctival injection, and bladder dysfunction.

Diagnosis

Diagnosis is challenging and follows established criteria, requiring a high index of suspicion. The process involves documenting a substantial increase in specific mast cell mediators during a symptomatic episode compared to a baseline asymptomatic state. Key laboratory tests include serum tryptase, plasma histamine, urinary N-methylhistamine, and urinary prostaglandin D2 metabolites, often processed at specialized reference laboratories like the Mayo Clinic or Viracor Eurofins. It is critical to rule out other conditions that cause similar symptoms, such as carcinoid syndrome, pheochromocytoma, medullary thyroid carcinoma, and vancomycin flushing syndrome. Bone marrow biopsy with assessment for CD25 expression and KIT D816V mutation analysis is typically indicated to exclude systemic mastocytosis and identify primary clonal disease.

Treatment and management

Management is multi-modal, focusing on blocking the effects of mast cell mediators and stabilizing mast cell membranes. First-line pharmacotherapy includes high-dose H1 antihistamines like cetirizine or fexofenadine, H2 antihistamines like famotidine, and mast cell stabilizers such as cromolyn sodium or ketotifen. Leukotriene receptor antagonists like montelukast are frequently added for refractory symptoms. For severe cases, targeted biologic therapies like the anti-IgE monoclonal antibody omalizumab have shown significant efficacy. Patients are also advised to maintain a detailed symptom diary to identify and avoid personal triggers, which may involve dietary modifications, stress reduction techniques, and environmental controls. Management often requires a collaborative approach involving specialists in allergy and immunology, hematology, and gastroenterology.

Prognosis and epidemiology

The prognosis of MCAS is variable and largely depends on the subtype, severity, and responsiveness to treatment. While not typically considered a direct cause of mortality, the condition can significantly impair quality of life and lead to debilitating chronic symptoms, with severe episodes posing a risk for life-threatening anaphylaxis. The epidemiology is not precisely defined due to historical under-recognition and diagnostic complexity, but it is believed to be more common than mastocytosis. Prevalence studies are ongoing, with some estimates suggesting it may affect a substantial portion of patients presenting with idiopathic anaphylaxis or multi-system chronic inflammatory symptoms. Increased awareness and refined diagnostic criteria are leading to more frequent identification across diverse patient populations.

Category:Immune system disorders Category:Allergology Category:Rare diseases